Julian Harrison
Stock Analyst at BTIG
(2.05)
# 2,905
Out of 4,761 analysts
41
Total ratings
36.36%
Success rate
-1.32%
Average return
Main Sectors:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVTX Avalo Therapeutics | Initiates: Buy | $40 | $8.44 | +373.93% | 1 | Dec 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $42 | $19.24 | +118.30% | 1 | Dec 19, 2024 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $11.02 | - | 3 | Dec 12, 2024 | |
| ANAB AnaptysBio | Downgrades: Neutral | n/a | $18.59 | - | 2 | Dec 2, 2024 | |
| OTLK Outlook Therapeutics | Maintains: Buy | $50 → $9 | $1.56 | +476.92% | 5 | Nov 29, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Buy | $8 | $2.24 | +257.14% | 4 | Nov 19, 2024 | |
| VYNE VYNE Therapeutics | Initiates: Buy | $8 | $2.74 | +191.97% | 1 | Nov 18, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $56 → $61 | $16.27 | +274.92% | 3 | Sep 26, 2024 | |
| RZLT Rezolute | Maintains: Buy | $13 → $15 | $4.53 | +231.13% | 2 | Sep 10, 2024 | |
| LQDA Liquidia | Maintains: Buy | $29 → $25 | $16.12 | +55.13% | 3 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $51 | $38.75 | +31.61% | 2 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.37 | - | 4 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $8.08 | +432.18% | 1 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $40 | $21.29 | +87.88% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $9.32 | +125.44% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $34.55 | +24.46% | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $4 | $1.80 | +122.22% | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $0.64 | +23,337.50% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $42.33 | -14.95% | 1 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $361.10 | - | 2 | Feb 11, 2022 |
Avalo Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $40
Current: $8.44
Upside: +373.93%
Cartesian Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $42
Current: $19.24
Upside: +118.30%
Keros Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $11.02
Upside: -
AnaptysBio
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $18.59
Upside: -
Outlook Therapeutics
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $1.56
Upside: +476.92%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $2.24
Upside: +257.14%
VYNE Therapeutics
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $2.74
Upside: +191.97%
Viridian Therapeutics
Sep 26, 2024
Maintains: Buy
Price Target: $56 → $61
Current: $16.27
Upside: +274.92%
Rezolute
Sep 10, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $4.53
Upside: +231.13%
Liquidia
Aug 20, 2024
Maintains: Buy
Price Target: $29 → $25
Current: $16.12
Upside: +55.13%
Jul 24, 2024
Maintains: Buy
Price Target: $41 → $51
Current: $38.75
Upside: +31.61%
Jun 17, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.37
Upside: -
May 20, 2024
Initiates: Buy
Price Target: $43
Current: $8.08
Upside: +432.18%
May 10, 2024
Maintains: Buy
Price Target: $32 → $40
Current: $21.29
Upside: +87.88%
Apr 12, 2024
Initiates: Buy
Price Target: $21
Current: $9.32
Upside: +125.44%
Dec 20, 2023
Initiates: Buy
Price Target: $43
Current: $34.55
Upside: +24.46%
Nov 29, 2023
Assumes: Buy
Price Target: $4
Current: $1.80
Upside: +122.22%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $0.64
Upside: +23,337.50%
Mar 9, 2023
Initiates: Buy
Price Target: $36
Current: $42.33
Upside: -14.95%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $361.10
Upside: -